September 2020. Volume 16. Number 3

Weak evidence in favour of oseltamivir in the treatment of influenza-like illness in primary care

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Butler CC, van der Velden AW, Bongard E, Saville BR, Holmes J, Coenen S, et al. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet. 2020;395:42-52.

Reviewers: Oltra Benavent M1, Ochoa Sangrador C2.
1Sección de Patología Infecciosa Infantil. Hospital Universitari i Politècnic La Fe. Valencia. España.
2Servicio de Pediatría. Complejo Asistencial de Zamora. Zamora. España.
Correspondence: Manuel Oltra Benavent . Email: oltra.benavent@gmail.com
Reception date: 24/06/2020
Acceptance date: 10/07/2020
Publication date: 29/07/2020

Abstract

Authors’ conclusions: treatment of patients affected by influenza-like illness in primary care with oseltamivir accelerates the recovery in an average of 1 day, being from 2 to 3 days in patients with older age, more severe symptoms, comorbidities and longer duration of previous symptoms.

Reviewers’ commentary: the intervention is applicable to the population attended in Primary Care in our setting. The size of the effect is moderate, even in risk subgroups, and its importance is more social and work-related than clinical. The quality of the evidence is moderate, although the level of recommendation will depend on the cost-effectiveness results.

How to cite this article

Oltra Benavent M, Ochoa Sangrador C. Débil evidencia a favor de oseltamivir en el tratamiento del síndrome gripal en Atención Primaria. Evid Pediatr. 2020;16:33.

AVC | Critically appraised articles

Butler CC, van der Velden AW, Bongard E, Saville BR, Holmes J, Coenen S, et al. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet. 2020;395:42-52.

Reviewers: Oltra Benavent M1, Ochoa Sangrador C2.
1Sección de Patología Infecciosa Infantil. Hospital Universitari i Politècnic La Fe. Valencia. España.
2Servicio de Pediatría. Complejo Asistencial de Zamora. Zamora. España.
Correspondence: Manuel Oltra Benavent . Email: oltra.benavent@gmail.com
Reception date: 24/06/2020
Acceptance date: 10/07/2020
Publication date: 29/07/2020

How to cite this article

Oltra Benavent M, Ochoa Sangrador C. Débil evidencia a favor de oseltamivir en el tratamiento del síndrome gripal en Atención Primaria. Evid Pediatr. 2020;16:33.

29/07/2020

Linked Comment